Meta-Analysis
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 6, 2022; 10(7): 2184-2193
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2184
Table 1 Basic characteristics of included studies
Ref.
Sample size
Gender (male)
Age (median, range), years
Country
Stage
Number of colon carcinoma
Treatment
Tumor type
Threshold
Endpoints
NOS
Cintin et al[20], 199960335569 (33-91)DenmarkDuke A-D355SurgeryCRC247 ug/L (upper 95th percentile)OS7
Cintin et al[21], 2002 32419268 (37-90)DenmarkDuke A-D197SurgeryCRC247 ug/L (upper 95th percentile)OS, PFS7
Liu et al[24], 2014864860 (38-76)ChinaTNMI I-IV34SurgeryCRC216 ng/mL (median)PFS6
Tarpgaard et al[27], 2014510301NRDenmarkTNM IV302Non-surgeryCRC155 ug/L (upper 95th percentile)OS, PFS7
Fuksiewicz et al[22], 2018835965 (25-82)PolandTNM I-IIINRSurgeryRC44.6 pg/mL (upper 95th percentile)OS, PFS6
Hermunen et al[23], 20201477560 (31-76)FinlandTNM II-IV87SurgeryCRC70.7 ng/mL (maximum Youden’s index)OS, PFS7
Peltonen et al[26], 202044126064.9 (33-84)DenmarkTNM IV258Surgery (liver resection)CRC34.8 ng/mL (upper 95th percentile)OS, PFS
Oh et al[25], 2021265134NRKoreaTNM I-IVNRSurgeryCRCPositive in tumor cellsOS, PFS7
Yang et al[28], 2021865660.12 ± 7.32 (mean ± SD)ChinaTNMI I-IV86SurgeryCCPositive in tumor cellsOS7
Table 2 Results of meta-analysis

No. of studies
HR
95%CI
P value
I2 (%)
P value
Overall survival81.801.32-2.45< 0.00190.3< 0.001
Treatment
Surgery71.991.27-3.120.00390.8< 0.001
Non-surgery11.171.05-1.300.004--
Tumor type
Colorectal carcinoma61.831.30-2.56< 0.00192.9< 0.001
Rectal carcinoma10.690.04-11.450.796--
Colon carcinoma11.811.13-2.900.013--
Source of YKL-40
Serum61.831.26-2.660.00192.7< 0.001
Tissue21.741.28-2.36< 0.0010.00.816
Progression-free survival71.621.22-2.160.00188.3< 0.001
Treatment
Surgery61.931.21-3.08.00587.8< 0.001
Non-surgery11.000.91-1.091.000--
Tumor type
Colorectal carcinoma61.641.22-2.200.00190.2< 0.001
Rectal carcinoma11.320.39-4.460.655--
Source of YKL-40
Serum61.541.15-2.070.00488.0< 0.001
Tissue12.001.36-2.94< 0.001--